Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study

Cancer Causes and Control

Volumn 25, Issue 5, 2014, Pages 625-632

  Lai, Gabriel Y ^a,b   Giovannucci, Edward L ^c,d   Pollak, Michael N ^e   Peskoe, Sarah B ^a   Stampfer, Meir J ^c,d   Willett, Walter C ^c,d   Platz, Elizabeth A ^a,f,g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C peptide; Leptin; Nested case control study; Prostate cancer; Risk

Indexed keywords

C PEPTIDE; LEPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; CELL GROWTH; COHORT ANALYSIS; INCIDENCE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; QUESTIONNAIRE; RISK FACTOR;

AGED; C-PEPTIDE; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEPTIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS;

EID: 84898852413     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0369-3     Document Type: Article

References (36)

1. Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91-106 (Pubitemid 32183103)
2. Hsing AW, Gao YT, Chua S, Deng J, Stanczyk FZ (2003) Insulin resistance and prostate cancer risk. J Natl Cancer Inst 95:67-71 (Pubitemid 36124297)
3. Hubbard JS, Rohrmann S, Landis PK et al (2004) Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore Longitudinal Study of Aging. Urology 63:253-258 (Pubitemid 38234413)
4. Hammarsten J, Hogstedt B (2005) Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41:2887-2895 (Pubitemid 41713128)
5. Hammarsten J, Damber JE, Peeker R, Mellstrom D, Hogstedt B (2010) A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer epidemiol 34:574-579
6. Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A (2012) Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care 35:1538-1543
7. Bonser AM, Garcia-Webb P (1984) C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 19:297-352
8. Borugian MJ, Spinelli JJ, Sun Z et al (2007) Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomark Prev 16:2164-2165 (Pubitemid 47621196)
9. Stocks T, Lukanova A, Rinaldi S et al (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120:2678-2686 (Pubitemid 46651291)
10. Lai GY, Helzlsouer KJ, Clipp SL, Rifai N, Platz EA (2010) Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Phila). 3:1334-1341
11. Neuhouser ML, Till C, Kristal A et al (2010) Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) 3:279-289
12. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039-1047
13. Freedland SJ, Giovannucci E, Platz EA (2006) Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 17:5-9 (Pubitemid 43083664)
14. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17:989-1003 (Pubitemid 44290764)
15. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G (2002) Analysis of paradoxical observations on the association between leptin and insulin resistance. Faseb J. 16:1163-1176 (Pubitemid 34815404)
16. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantozoros CS (1998) Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 76:25-28 (Pubitemid 28164564)
17. Hsing AW, Chua S, Gao YT et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93:783-789 (Pubitemid 32514802)
18. Stattin P, Kaaks R, Johansson R et al (2003) Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomark Prev 12:474-475 (Pubitemid 36578490)
19. Baillargeon J, Platz EA, Rose DP et al (2006) Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomark Prev 15:1331-1335 (Pubitemid 44125290)
20. Li H, Stampfer MJ, Mucci L et al (2010) A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56:34-43
21. Touvier M, Fezeu L, Ahluwalia N et al (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 177:3-13
22. Burton A, Martin RM, Holly J et al (2013) Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the Protect study. Cancer Causes Control 24:323-334
23. Stattin P, Soderberg S, Hallmans G et al (2001) Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86:1341-1345 (Pubitemid 32323026)
24. Fowke JH, Motley S, Dai Q, Concepcion R, Barocas DA (2013) Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer: evidence of effect modification by prostate size. Cancer Lett 328:345-352
25. DeLellis HK, Rinaldi S, Kaaks R, Kolonel L, Henderson B, Le Marchand L (2007) Lifestyle and dietary correlates of plasma insulin-like growth factor binding protein-1 (IGFBP-1), leptin, and C-peptide: the multiethnic cohort. Nutr Cancer 58:136-145 (Pubitemid 47328765)
26. Bandaru P, Shankar A (2011) Association between plasma leptin levels and diabetes mellitus. Metab Syndr Relat Disord 9:19-23
27. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. Int J Cancer 121:1571-1578 (Pubitemid 47328718)
28. Patel AR, Klein EA (2009) Risk factors for prostate cancer. Nat Clin Pract 6:87-95
29. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E (2005) Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16:255-262 (Pubitemid 40897844)
30. Platz EA, Leitzmann MF, Rifai N et al (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomark Prev 14:1262-1269 (Pubitemid 40656478)
31. Platz EA, Clinton SK, Giovannucci E (2008) Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123:1693-1698
32. Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094-1102 (Pubitemid 44851745)
33. Considine RV (2005) Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin Vasc Med 5:15-24 (Pubitemid 40721041)
34. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15:2056-2062 (Pubitemid 44877026)
35. Kaaks R, Lukanova A, Rinaldi S et al (2003) Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 12:309-315 (Pubitemid 36994086)
36. Ruhl CE, Everhart JE (2001) Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 74:295-301 (Pubitemid 32802013)